Syros Pharmaceuticals, Inc. (SYRS) Upgraded at Zacks Investment Research, Report finds

Syros Pharmaceuticals, Inc. (SYRS) Upgraded at Zacks Investment Research, Report finds

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other analysts have also issued reports on SYRS. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Thursday, December 15th. Cann restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, December 12th. Piper Jaffray Companies set a $20.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 14th. Finally, Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.00.

Syros Pharmaceuticals (NASDAQ:SYRS) traded down 0.37% during midday trading on Wednesday, reaching $10.65. 59,847 shares of the company traded hands. The firm’s 50 day moving average price is $11.84 and its 200 day moving average price is $12.80. The firm’s market capitalization is $249.00 million. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. On average, analysts expect that Syros Pharmaceuticals will post ($5.56) earnings per share for the current year.

Several hedge funds have recently modified their holdings of the stock. Deerfield Management Co. acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $38,028,000. Flagship Ventures Fund IV General Partner LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $87,241,000. Redmile Group LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $15,058,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $193,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $1,892,000. Institutional investors and hedge funds own 54.51% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment

Syros Pharmaceuticals, Inc. (SYRS) Upgraded at Zacks Investment Research

Syros Pharmaceuticals, Inc. (SYRS) Upgraded at Zacks Investment Research

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other analysts have also issued reports on SYRS. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Thursday, December 15th. Cann restated a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, December 12th. Piper Jaffray Companies set a $20.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 14th. Finally, Wedbush restated an “outperform” rating and issued a $18.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.00.

Syros Pharmaceuticals (NASDAQ:SYRS) traded down 0.37% during midday trading on Wednesday, reaching $10.65. 59,847 shares of the company traded hands. The firm’s 50 day moving average price is $11.84 and its 200 day moving average price is $12.80. The firm’s market capitalization is $249.00 million. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. On average, analysts expect that Syros Pharmaceuticals will post ($5.56) earnings per share for the current year.

Several hedge funds have recently modified their holdings of the stock. Deerfield Management Co. acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $38,028,000. Flagship Ventures Fund IV General Partner LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $87,241,000. Redmile Group LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at $15,058,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $193,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $1,892,000. Institutional investors and hedge funds own 54.51% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment